RET and medullary thyroid gland carcinoma: Experimental evidence and clinical observations from the LIBRETTO-0012 trial suggest that the RET p.632_633del mutation is neither rare in patients with medullary thyroid cancer (MTC) nor is it resistant to therapeutic intervention with the highly selective and potent REarranged during Transfection (RET)-inhibitor selpercatinib, a conclusion that is contrary to that presented in the mentioned case report.